VolitionRx Q3 revenue $475K, up 187% YoY; sold >110K Nu.Q Vet tests in 9 months

VOLITIONRX LTD

2025-Q3 EPS reported -$0.25 vs consensus -$0.90 ▲ beat (+72.1%)

Q3 2024 revenue $475K, up 187% YoY; YTD revenue $1M, up 96%.
Nu.Q Vet revenue up 307% in Q3; >110,000 tests sold in first 9 months of 2024.
Cash used in operations $5.4M in Q3, down 36% YoY; cash balance $5.4M at Sept 30.
Received >$2.2M in non-dilutive funding commitment from Walloon Region post-quarter.
Reaffirms goal to be cash neutral (income matching expenditure) in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.